Gender differences in antipsychotic treatment of patients with schizophrenia-related disorders: endocrinological aspects


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review discusses the role of gender in the issue of the effectiveness and tolerability of pharmacotherapy in patients with schizophrenia-related disorders. It is shown that female patients are more «vulnerable» for the formation of a number of neuroendocrine dysfunctions (NED). Data on the biological basis of gender differences, frequency of occurrence and clinical features of NED in this category of patients are examined. It is emphasized that the problem of tolerability is now more relevant and significant in comparison with the effectiveness of antipsychotics, because intolerance or poor tolerance is one of the most common reasons for nonadherence to therapy up to the complete abandonment of it.

全文:

受限制的访问

参考

  1. Аведисова А.С., Ахапкин Р.В. Проблемы клинической оценки переносимости терапии психотропными препаратами. Психиатрия и психофармакотерапия. Журнал им. П.Б. Ганнушкина. 2005;7(1):17-20.
  2. Горобец Л.Н. Эндокринологические аспекты проблемы переносимости нейролептической терапии у больных шизофренией (возрастные и гендерные факторы). Психиатрия и психофармакотерапия. Журнал им. П.Б. Ганнушкина. 2012;14(1):41-7.
  3. Клиническое руководство: модели диагностики и лечения психических и поведенческих расстройств. Под ред. В.Н. Краснова и И.Я. Гуровича. Сост. в Моск. НИИ психиатрии МЗ РФ. Приложение к журналу «Социальная и клиническая психиатрия». М., 1999. 224 с.
  4. Cadenhead K.S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and can nabis in a vulnerable population. Psychiatry Res. 2011;188(2):208-16.
  5. Moriarty P.J., Lieber D., Bennett A., White L., Parrella M., Harvey P.D., Davis K.L. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr. Bull. 2001;27(1):103-13.
  6. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a 1rst episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999;156:544-49.
  7. Smith S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry. 2010; 22(5):472-84.
  8. Weizman R., Weizman A., Levi J., Gura V., Zevin D., Maoz B., Wijsenbeek H., Ben David M. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemo dialysis. Psychosom. Med. 1983;45:259-69.
  9. Haack S., Seeringer A., Thormann P.A., Becker T., Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10(9):1511-26.
  10. Groleger U., Novak-Grubic V. Gender, psychosis and psychotropic drugs: differences and similarities. Psychiatr. Danub. 2010;22 (2):338-42.
  11. Kolakowska T., Williams A.O., Ardern M., Reveley M.A., Jambor K., Gelder M.G., Mandelbrote B.M. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br. J. Psychiatry. 1985;146:229-39.
  12. Seeman M.V. Current outcome in schizophrenia: women vs men. Acta Psychiatr. Scand. 1986;73:609-17.
  13. Wong D.F., Wagner H.N. Jr., Dannals R.F., Links J.M., Frost J.J., Ravert H.T., Wilson A.A., Rosenbaum A.E., Gjedde A., Douglass K.H. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984;226(4681):1393-96.
  14. Горобец Л.Н. Нейроэндокринные дисфункции и нейролептическая терапия. М.: ИД «Медпрактика-М», 2007. 312 с.
  15. Aichhorn W., Gasser M., Weiss E.M., Hinterhuber H., Marksteiner J. Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr. Neuropharmacol. 2005;3:73-85.
  16. Andia A.M., Zisook S., Heaton R.K., Hesselink J., Jernigan T., Kuck J., Morganville J., Braff D.L. Gender differences in schizophrenia. J. Nerv. Ment. Dis. 1995;183:522-28.
  17. Saad M.F., Damani S., Gingerich R.L. Sexual dimorphism in plasma leptin concentration. J. Clin. Endocrinol. Metab. 1997;82:579-84.
  18. Suzuki T., Remington G., Uchida H., Rajji T.K., Graff-Guerrero A., Mamo D.C. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 2011;28(12):961-80.
  19. Castle D.J., Abel K., Takei N., Murray R.M. Gender differences in schizophrenia: Hormonal effect or subtypes? Schizophr. Bull. 1995;21:1-12.
  20. Melkersson K., Hulting A.L., Hall K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrinol. Lett. 1999;20:199-204.
  21. Szymanski S., Lieberman J.A., Alvir J.M., Mayerhoff D., Loebel A., Geisler S., Chakos M., Koreen A., Jody D., Kane J. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenia patients. Am. J. Psychiatry. 1995; 152:698-703.
  22. Seeman M.V. Interaction of sex, age, and neuroleptic dose. Compr. Psychiatry. 1983;24:125-28.
  23. Meltzer H.Y., Busch D.A., Fang V.S. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 1983;9:271-83.
  24. Nathan R.S., Sachar E.J., Ostrow L., Asnis G.M., Halbreich U., Halpern F., Renzi N.L., Slotnick V. A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Psychopharmacology. 1983;80(1):46-9.
  25. Halbreich U., Asnis G., Goldstein S., Nathan R.S., Zander K., Herne J.V. Sex differences in response to psychopharmacological interventions in humans. Psychopharmacol. Bull. 1984;20(3):526-30.
  26. Koreen A.R., Lieberman J., Alvir J., Mayerhoff D., Loebel A., Chakos M., Amin F., Cooper T. Plasma homovanillic acid levels in 1rst episode schizophrenia. Psychopathology and treatment response. Arch. Gen. Psychiatry. 1994; 51:132-38.
  27. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: Relation to neurolepticresistance. Biol. Psychiatry. 1997;41:560-66.
  28. Yasui N., Kondo T., Otani K., Ishida M., Mihara K., Suzuki A., Kaneko S., Inoue Y. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol. Toxicol. 1998;82:153-56.
  29. Buckman M.T., Peake G.T. Estrogen potentiation of phenothiazine-induced prolactin secretion in man. J. Clin. Endocrinol. Metabol. 1973;37(6):977-80.
  30. Kulkarni J., Gavrilidis E., Hayes E., Heaton V., Worsley R. Special biological issues in the management of women with schizophrenia. Expert Rev. Neurother. 2012;12(7):823-33.
  31. Salem J.E., Kring A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin. Psychol. Rev. 1998;18(7):795-819.
  32. Al-Issa I. Sex differences in the aetiology of schizophrenia. Int. Rev. Appl. Psychology. 1985;34:315-33.
  33. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 1990;16:185-94.
  34. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry. 1991;148:1474-85.
  35. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000;401:3-38.
  36. Hogarty G.E., Goldberg S.C., Schooler N.R., Ulrich R.F. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch. Gen. Psychiatry. 1974; 31(5):603-18.
  37. Chouinard G., Annable L., Steinberg S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J. Clin. Psychopharmacol. 1986;6(1):21-6.
  38. D'Mello D.A., McNeil J.A. Sex differences in bipolar affective disorder: neuroleptic dosage variance. Compr. Psychiatry. 1990;31(1):80-3.
  39. Meltzer H.Y. The role of dopamine in schizophrenia. Lindenmayer J.P., Kay S.R. (Eds.). New biological vistas on schizophrenia. New York: Bruner/Mazel. 1992:131-57.
  40. Heitmiller D.R., Nopoulos P.C., Andreasen N.C. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr. Res. 2004;66:137-42.
  41. Parellada E., Lomena F., Catafau A.M., Bernardo M., Font M., Fern6ndez-Egea E., Pavнa J., Gutierrez F. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psych. Res. 2004;130:79-84.
  42. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry. 2010;22:417-28.
  43. Salokangas R.K. Gender and the use of neuroleptics in schizophrenia. Further testing of the estrogen hypothesis. Schizophr. Res. 1995:16(1):7-16.
  44. Szymanski S., Lieberman J., Pollack S., Kane J.M., Safferman A., Munne R., Umbricht D., Woerner M., Masiar S., Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol. Psychiatry. 1996; 39:249-54.
  45. Angermeyer M.C., Kuhn L., Goldstein J.M. Gender and the course of schizophrenia: Differences in treated outcomes. Schizophr. Bull. 1990;16(2):293-304.
  46. Вильянов В.Б. Гендерный фактор и эффективность современных антипсихотиков при лечении больных шизофренией. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2004;2:18-20.
  47. Magharious W., Goff D.C., Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 1998;77:159-66.
  48. Pinals D.A., Malhotta A.K., Missar C.D., Pickar D., Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr. Res. 1996;22:215-22.
  49. Gur R.E., Gur R.C. Gender differences in regional cerebral blood flow. Schizophr. Bull. 1990;16:247-54.
  50. Pohjalainen T., Rinne J.O., Nagren K., Syvolahti E., Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am. J. Psychiatry. 1998;155:768-73.
  51. Perry P.J., Miller D.D., Arnott S.V., Cadoret R.J. Clozapine and norclozapine plasma concentra tions and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry. 1991;148:231-35.
  52. Hasegawa M., Gutierrez-Esteinon R., Way L., Meltzer H.Y. Relationship between clinical eficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J. Clin. Psychopharmacol. 1993;13:383-90.
  53. Lieberman J.A., Kane J.M., Safferman A.Z., Pollack S., Howard A., Szymanski S., Masiar S.J., Kronig M.H., Cooper T., Novacenko H. Predictors of response to clozapine. J. Clin. Psychiatry. 1994;55(9, suppl. B):126-28.
  54. Haring C., Meise U., Humpel C., Saria A., Fleischhacker W.W., Hinterhuber H. Dose-related plasma levels of clozapine: In.uence of smoking, behavior, sex and age. Psychopharmacology. 1989;99:S38-40.
  55. Kane J.M., Cooper T.B., Sacher E.J., Halpern F.S., Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology. 1981;73(2):184-87.
  56. Jann M.W., Grimsley S.R., Gray E.C., Chang W.H. Pharmacokinetics and pharmacodynamics of clozapine. Clin. Pharmacokinet. 1993; 24(2):161-76.
  57. Curtis V.A., Wright P., Reveley A., Kerwin R., Lucey J.V. Effect of clozapine on d-fefluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 1995;166(5):642-46.
  58. Goldstein J.M., Cohen L.S., Horton N.J., Lee H., Andersen S., Tohen M., Crawford A., Tollefson G. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.
  59. Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии. Рациональная психофармакотерапия в психиатрической практике. Руководство для практикующих врачей под ред. Ю.А. Александровского и Н.Г. Незнанова. М.: Издательство «Литтерра». 2014. С. 802-23.
  60. Kleinberg D.L., Davis J.M., De Coster R. Prolactine levels and adverse events in patients treated with risperidone. Clin. Psychopharmacol. 1999;19:57-64.
  61. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 2000;22:1085-96.
  62. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry. 2001;62:231-38.
  63. Grunder G., Wetzel H., Schlosser R. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol. Psychiatry. 1999;45(1):89-97.
  64. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., Garcia-Portilla M.P., Fernandez I., Hernandez G.; EIRE Study Group. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res. 2003;62:77-88.
  65. Reiser L.W., Reiser M.F. Endocrine disorders. Comprehensive Textbook of Psychiatry. New York. 1984:1024-35.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##